Q3 2025 13F Holders as of 9/30/2025
-
Type / Class
-
Equity / COMMON-STOCK
-
Shares outstanding
-
72.2M
-
Number of holders
-
96
-
Total 13F shares, excl. options
-
52.8M
-
Shares change
-
-2.87M
-
Total reported value, excl. options
-
$79.7M
-
Value change
-
-$3.99M
-
Number of buys
-
40
-
Number of sells
-
-52
-
Price
-
$1.51
Significant Holders of Zentalis Pharmaceuticals, Inc. - COMMON-STOCK (ZNTL) as of Q3 2025
119 filings reported holding ZNTL - Zentalis Pharmaceuticals, Inc. - COMMON-STOCK as of Q3 2025.
Zentalis Pharmaceuticals, Inc. - COMMON-STOCK (ZNTL) has 96 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 52.8M shares
of 72.2M outstanding shares and own 73.08% of the company stock.
Largest 10 shareholders include Matrix Capital Management Company, LP (14M shares), VANGUARD GROUP INC (2.9M shares), ACADIAN ASSET MANAGEMENT LLC (2.85M shares), RENAISSANCE TECHNOLOGIES LLC (2.33M shares), CITADEL ADVISORS LLC (2.08M shares), TANG CAPITAL MANAGEMENT LLC (1.55M shares), BANK OF AMERICA CORP /DE/ (1.55M shares), TWO SIGMA ADVISERS, LP (1.46M shares), D. E. Shaw & Co., Inc. (1.41M shares), and MORGAN STANLEY (1.41M shares).
This table shows the top 96 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.